UPDATE 2-Vectura's therapy misses primary goal in late stage lung disease trial

Aug 30 (Reuters) - Drugmaker Vectura Group Plc said

its asthma therapy Flutiform had not met the primary endpoint in

a late-stage trial to determine its ability to treat COPD, a

type of lung disease, sending the British firm's stock to its

lowest in 21 months.

Read more